Abstract

Whereas thrombocytopenia is a common and recognized cause of abnormal primary hemostasis, qualitative defects and platelets exist. These disorders may be acquired defects from aspirin or other antiplatelet drugs or from congenital defects. The latter are multiple, rare, and esoteric. Yet understanding these disorders has revealed substantial information about platelet metabolism and physiology that has been translated into therapeutically reproducing these defects when weakened platelets are clinically desirable, as in patients with cardiac and/or central nervous system ischemia.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.